AbbVie doubles down on siRNA with $335M upfront bet on ADARx
After getting into siRNA work with its $1.4 billion acquisition of Aliada Therapeutics late last year, AbbVie is beefing up its presence in the hot subfield of genetic medicines. On Wednesday, AbbVie ...
After getting into siRNA work with its $1.4 billion acquisition of Aliada Therapeutics late last year, AbbVie is beefing up its presence in the hot subfield of genetic medicines.
On Wednesday, AbbVie ...
